跳至主要内容
临床试验/NCT00556257
NCT00556257撤回2 期

A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients

Pfizer0 个研究点开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
Pfizer
主要终点
Clinical biopsy proven acute rejection rate at 6 months

研究概览

简要总结

A new immunosuppressive drug based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant patients for 12 months in addition to other standard transplant medications such as prednisone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Recipient of first time kidney transplant
  • Between the ages of 18 and 70 years, inclusive

排除标准

  • Recipient of any non-kidney transplant

研究组 & 干预措施

Treatment Arm 1

Active Comparator

Treatment Arm 1 will also receive standard of care medications.

干预措施: Cyclosporine (Drug)

Treatment Arm 2

Experimental

Treatment Arm 2 will also receive select standard of care medications.

干预措施: CP-690-,550 (Drug)

结局指标

主要结局

Clinical biopsy proven acute rejection rate at 6 months

时间窗: 6 months

次要结局

  • Pharmacokinetics of CP-690,550(12 months)
  • Lymphocyte subsets(12 months)
  • Posttransplant humoral alloreactivity(12 months)
  • Safety and tolerability of CP-690,550(12 months)

研究者

发起方
Pfizer
申办方类型
Industry

相似试验